You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ENKTL

Showing 1 - 25 of 30
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

Not yet recruiting
  • Extranodal NK/T Cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 16, 2022

Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

Available
  • Extranodal NK/T-cell Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 18, 2022

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Safety and Efficacy Trial in Guangzhou (Sintilimab, Chidamide, Azacitidine)

Not yet recruiting
  • Safety and Efficacy
  • Guangzhou, Guangdong, China
    Department of Medical Oncology,Sun Yat-sen University Cancer Cen
Aug 16, 2021

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Guangzhou (Pegaspargase, Anti-PD-1 mAb, Definitive intensity-modulated

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

Lymphoma Trial in Philadelphia (Pembrolizumab)

Withdrawn
  • Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
May 5, 2021

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
May 7, 2022

Lymphoma Trial in Changsha (pegaspargase, Gemcitabine, Oxaliplatin)

Unknown status
  • Lymphoma
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jan 25, 2020

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Unknown status
  • Extranodal NK/T-cell Lymphoma
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 12, 2020

    Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

    Active, not recruiting
    • Lymphoma, Extranodal NK-T-Cell
    • Seoul, Korea, Republic of
      81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
    Sep 22, 2021

    Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

    Active, not recruiting
    • Extranodal NK/T Cell Lymphoma, Nasal Type
    • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
    • Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 10, 2022

    Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Guangzhou (pegaspargase, Gemcitabine, Oxaliplatin)

    Recruiting
    • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
    • Guangzhou, Guangdong, China
      Department of Medical Oncology, Sun Yat-sen University Cancer Ce
    Mar 12, 2021

    Effect of Drugs Trial in Nanjing (Sintilimab)

    Completed
    Has Results
    • Effect of Drugs
    • Nanjing, Jiangsu, China
      Jiangsu Provincial Hospital
    Dec 20, 2020

    Extranodal NK-T-Cell Lymphoma Trial in Seoul (Etoposide, Ifosfamide, Dexamethasone)

    Unknown status
    • Extranodal NK-T-Cell Lymphoma
    • Seoul, Seoul, Korea, Republic Of, Korea, Republic of
    • +1 more
    Oct 21, 2020

    Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

    Recruiting
    • Epstein-Barr Virus Associated Lymphoproliferative Disorder
    • +7 more
    • Nanatinostat in combination with valganciclovir
    • Birmingham, Alabama
    • +57 more
    Aug 10, 2022

    Infectious Diseases, Hematological Malignancies Trial in Hangzhou (LMP1 CAR T-cells)

    Not yet recruiting
    • Infectious Diseases
    • Hematological Malignancies
    • LMP1 CAR T-cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital，College of Medicine, Zhejiang Univ
    Dec 5, 2020

    Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • PK Blood Collection
    • +2 more
    • (no location specified)
    Nov 1, 2022

    Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)

    Active, not recruiting
    • Extranodal NK/T-cell Lymphoma, Nasal Type
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Aug 19, 2021

    Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • CAR-T Therapy
    • Hefei, Anhui, China
    • +7 more
    Jul 31, 2023

    Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma Trial in

    Recruiting
    • Natural Killer/T-cell Lymphoma
    • +2 more
    • Seoul, Kangnamgu, Korea, Republic of
      Samsung Medical Center
    Sep 22, 2021

    Treatment Refusal Trial in Guangzhou (P-CHOP, Radiotherapy)

    Terminated
    • Treatment Refusal
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 8, 2018

    Treatment Refusal Trial in Guangzhou (Gemcitabine, etoposide, Pegaspargase)

    Unknown status
    • Treatment Refusal
    • Guangzhou, Please Select, China
      Sun Yat-sen University Cancer Center
    Dec 16, 2020